# BPaL(M) Regimen for the Treatment of MDR/RR-TB

> **NCT05381194** · PHASE4 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 80 (estimated)

## Conditions studied

- Multidrug- and Rifampicin-resistant Tuberculosis

## Interventions

- **DRUG:** BPaL(M) regimen

## Key facts

- **NCT ID:** NCT05381194
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-13
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-03-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381194, "BPaL(M) Regimen for the Treatment of MDR/RR-TB". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05381194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*